Optimer grosses $60m as it exits Taiwanese operation

Optimer Pharmaceuticals has fully divested its remaining stake in the US firm's formerly wholly owned Taiwanese subsidiary Optimer Biotechnology Inc (OBI), as part of an ongoing effort to streamline operations and raise funds.

Optimer Pharmaceuticals has fully divested its remaining stake in the US firm's formerly wholly owned Taiwanese subsidiary Optimer Biotechnology Inc (OBI), as part of an ongoing effort to streamline operations and raise funds.

As of 30 June Optimer held a non-controlling 43.6% interest in OBI, but said that it would realise gross proceeds...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

More from Therapeutic Category